Luye Pharma Group announced today that its innovative formulation Lipusu® has been included in category B of the 2020 Chinese National Reimbursement Drug List (NRDL), which will further improve the drug’s accessibility to patients. All indications of Lipusu®, including non-small cell lung cancer, breast cancer and ovarian cancer are reimbursable in accordance with the NRDL.
Lipusu® is a nano paclitaxel liposome formulation. It is the first paclitaxel liposome formulation to be commercialized and the only paclitaxel liposome formulation currently available in the world. With its unique ability to target tumors and lymph nodes and a relatively long half-life, the drug is a more potent anticancer agent with better drug safety and tolerance.
In the past 16 years since going on the market, Lipusu® has been administered to over 2 million patients and has been widely recognized by doctors and patients for its proven efficacy and comparative safety in long-term clinical practice. According to the latest post-market clinical research results, Lipusu® combined with Cisplatin has shown equivalent efficacy and better safety and drug compliance when compared with Gemcitabine combined with Cisplatin for the first-line treatment of advanced squamous cell lung carcinoma.
The value of Lipusu® has achieved widespread acknowledgement and has been recommended by multiple authoritative guidelines and expert consensuses. Previously, Lipusu® was recommended as a first-line treatment by the 2020 CSCO Guidelines on Diagnosis and Treatment of Breast Cancer, the 2019 CSCO Guidelines on Diagnosis and Treatment of Primary Lung Cancer, and was also included in the Expert Consensus on the Clinical Application of Taxanes for the Treatment of Gynecologic Malignancies and the Expert Consensus on the Clinical Application of Taxanes for the Treatment of Breast Cancer (2020). In addition, Lipusu® was included in the China Guidelines on Radiotherapy for Esophageal Cancer (2019) as the primary choice for multiple combination radiotherapies.
“The inclusion of Lipusu® on the NRDL demonstrates that the Chinese National Healthcare Security Administration has recognized the drug’s clinical value, novelty and benefit to patients, among other factors. Its inclusion on the NRDL will further improve the drug’s affordability to patients, while improving accessibility”, said a management representative from Luye Pharma Group. “We will continue to expand Lipusu®’s coverage in both broader markets and segment markets, as well as actively promote relative clinical academic research to allow more patients to benefit from this high-quality and innovative product.”
Luye Pharma Group announced today that its innovative formulation Lipusu® has been included in category B of the 2020 Chinese National Reimbursement Drug List (NRDL), which will further improve the drug’s accessibility to patients. All indications of Lipusu®, including non-small cell lung cancer, breast cancer and ovarian cancer are reimbursable in accordance with the NRDL.
Lipusu® is a nano paclitaxel liposome formulation. It is the first paclitaxel liposome formulation to be commercialized and the only paclitaxel liposome formulation currently available in the world. With its unique ability to target tumors and lymph nodes and a relatively long half-life, the drug is a more potent anticancer agent with better drug safety and tolerance.
In the past 16 years since going on the market, Lipusu® has been administered to over 2 million patients and has been widely recognized by doctors and patients for its proven efficacy and comparative safety in long-term clinical practice. According to the latest post-market clinical research results, Lipusu® combined with Cisplatin has shown equivalent efficacy and better safety and drug compliance when compared with Gemcitabine combined with Cisplatin for the first-line treatment of advanced squamous cell lung carcinoma.
The value of Lipusu® has achieved widespread acknowledgement and has been recommended by multiple authoritative guidelines and expert consensuses. Previously, Lipusu® was recommended as a first-line treatment by the 2020 CSCO Guidelines on Diagnosis and Treatment of Breast Cancer, the 2019 CSCO Guidelines on Diagnosis and Treatment of Primary Lung Cancer, and was also included in the Expert Consensus on the Clinical Application of Taxanes for the Treatment of Gynecologic Malignancies and the Expert Consensus on the Clinical Application of Taxanes for the Treatment of Breast Cancer (2020). In addition, Lipusu® was included in the China Guidelines on Radiotherapy for Esophageal Cancer (2019) as the primary choice for multiple combination radiotherapies.
“The inclusion of Lipusu® on the NRDL demonstrates that the Chinese National Healthcare Security Administration has recognized the drug’s clinical value, novelty and benefit to patients, among other factors. Its inclusion on the NRDL will further improve the drug’s affordability to patients, while improving accessibility”, said a management representative from Luye Pharma Group. “We will continue to expand Lipusu®’s coverage in both broader markets and segment markets, as well as actively promote relative clinical academic research to allow more patients to benefit from this high-quality and innovative product.”
